- Remove this product from my favorite's list.
- Add this product to my list of favorites.
Products
Newsletter
Background
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3),which belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.
Source
Recombinant Biotinylated Human TIGIT, Fc,Avitag (MALS verified) (TIT-H82F1) is expressed from human 293 cells (HEK293). It contains AA Met 22 - Pro 141 (Accession # Q495A1-1).
Predicted N-terminus: Met 22
Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 41.3 kDa. As a result of glycosylation, the protein migrates as 45-55 kDa under reducing (R) condition, and 85-115 kDa under non-reducing (NR) condition (SDS-PAGE).
Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Endotoxin
Less than 1.0 EU per μg by the LAL method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Bioactivity
Please refer to product data sheet.
(1) "TIGIT reverses IFN-α-promoted Th1-like Tregs via in-sequence effects dependent on STAT4"
Yu, Gu, Wang et al
Arthritis Res Ther (2023) 25 (1), 221
(2) "A circadian clock gene-related signature for predicting prognosis and its association with sorafenib response in hepatocellular carcinoma"
Liang, Ye, Li et al
Transl Cancer Res (2023) 12 (10), 2493-2507
(3) "PD1+TIGIT+2B4+KLRG1+ cells might underlie T-cell dysfunction in patients treated with BCMA-directed CAR-T therapy"
Mishra, Schmidt, Martell et al
Transplant Cell Ther (2023)
Showing 1-3 of 1368 papers.
Follow us